Interleukin-17A
Cross-source consensus on Interleukin-17A from 1 sources and 5 claims.
1 sources · 5 claims
How it works
Evidence quality
Highlighted claims
- The protocol treats knee-focused preclinical evidence as mechanistic plausibility rather than direct proof of efficacy in erosive hand osteoarthritis. — Efficacy of Vunakizumab in Erosive haNd osteoarthritiS (VENuS): protocol for a multicentre, randomised controlled trial
- IL-17A concentrations are higher in osteoarthritis serum and synovial fluid than in healthy controls and correlate with clinical severity measures. — Efficacy of Vunakizumab in Erosive haNd osteoarthritiS (VENuS): protocol for a multicentre, randomised controlled trial
- The trial’s rationale is based on evidence that the interleukin-17 cytokine family contributes to osteoarthritis pathogenesis. — Efficacy of Vunakizumab in Erosive haNd osteoarthritiS (VENuS): protocol for a multicentre, randomised controlled trial
- IL-17 is linked to inflammatory, complement, hypoxia, angiogenesis, and glycolytic pathways in osteoarthritis cells. — Efficacy of Vunakizumab in Erosive haNd osteoarthritiS (VENuS): protocol for a multicentre, randomised controlled trial
- In vitro evidence shows IL-17 increased expression of matrix metalloproteinases and inflammatory proteins. — Efficacy of Vunakizumab in Erosive haNd osteoarthritiS (VENuS): protocol for a multicentre, randomised controlled trial